CTLA4 and cancer: Considering above mentioned issues, it seems that suppressing CTLA-4 expression on DCs along with loading these cells with a tumor cell lysate increases anti-tumoral specific T cell responses more efficiently, suggesting that this could be a possible and applicable cancer immunotherapy strategy.